Laurus Labs Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Laurus Labs Ltd. on BSE

Load latest

Laurus Labs Ltd.

19 May 2017, 05:45PM

601.15

1.33%

Company Update

Updates

BSE India

The API facility of the Unit 2 has completed successful USFDA inspection without any 483 and the formulations unit in the same facility received EIR (Establishment Inspection Report) on May 18, 2017

pdf

Laurus Labs Ltd.

19 May 2017

601.15

1.33%

Annual Report

Annual report for Laurus Labs Ltd. for FY-2017

pdf

Laurus Labs Ltd.

18 May 2017

601.15

1.33%

Company Update

Press Release

BSE India

Press Release dated 18th May 2017 is attached

pdf

Laurus Labs Ltd.

18 May 2017

601.15

1.33%

Corp. Action

Laurus Labs Ltd has informed BSE that the Board of Directors of the Company in their Meeting held on May 18, 2017, inter alia, have recommended a dividend of Rs. 1.50 (15%) per equity share of Rs.10/- face value, for the financial year 2016-17. The dividend on equity shares, if declared by the shareholders at the ensuing Annual General Meeting, will be credited/ dispatched on or after July 18, 2017.

pdf

Laurus Labs Ltd.

18 May 2017

601.15

1.33%

Company Update

Updates

BSE India

Investor Presentation is attached

pdf

Laurus Labs Ltd.

18 May 2017

601.15

1.33%

Board Meeting

Outcome of Board Meeting

BSE India

Outcome of the Board Meeting 18th May 2017 1. Audited Financial Results for the Quarter and Year ended March 31, 2017 2. Dividend for FY 2017 3. Appointment of Independent Directors 4. Submission of Quarterly/Year-to-date Consolidated Financial Results

pdf

Laurus Labs Ltd.

17 May 2017

601.15

1.33%

Company Update

Updates

BSE India

Laurus Labs will organize a conference call for investors and analysts on Friday, May 19, 2017 at 11 am IST. Dial-in details of the conference call are as follows: Primary number+91 22 3938 1071 India Local access Number3940 3977 Available in - Ahmedabad, Bangalore, Chandigarh, Chennai, Gurgaon (NCR), Hyderabad, Kochi/Cochin, Kolkata, Lucknow, Pune Accessible from all carriers Singapore Toll Free Number800 101 2045 Hong Kong Toll Free...

pdf

Laurus Labs Ltd.

08 May 2017

601.15

1.33%

Company Update

Updates

BSE India

Laurus Labs Ltd. (the Company') wishes to intimate the Stock Exchanges that the Company's pharmaceutical formulation & marketing partner Natco Pharma Ltd (Natco') has launched the generic version of Sofosbuvir 400 mg/ Velpatasvir 100 mg fixed dose combination in India based on an API supplied by the Company. This is part of an agreement between the Company and Natco, wherein the net profit after the sale of this Hepatitis C related product is shared...

pdf

Laurus Labs Ltd.

08 May 2017

601.15

1.33%

Company Update

Change in Directorate

BSE India

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we regret to inform that Mr.Amal Ganguli , an independent Director and Non-Executive Chairman of the Company, passed away today after a prolonged illness. He was also the Chairman of the Audit Committee and Member of Nomination and Remuneration Committee and CSR Committee. Kindly take the same on record.

pdf

Laurus Labs Ltd.

08 May 2017

601.15

1.33%

Corp. Action

Board to consider Dividend

BSE India

Laurus Labs Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 18, 2017, inter alia, to consider and approve the Audited Financial Results of the Company for the Financial Year ended March 31, 2017 and to recommend Dividend, if any, on Equity Shares for the year ended March 31, 2017.Further, the Companys trading window for dealing in securities by the Directors and Designated Persons shall be...

pdf

Is Laurus Labs Ltd. worth buying?

1219 Votes:

Buy 79.57%

Sell 10.83%

Hold 9.6%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf